The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/Objective-Transplant-associated arteriosclerosis manifests as progressive vascular neointimal expansion throughout the arterial system of allografted solid organs, and eventually compromises graft perfusion and function. Allografts placed in colony stimulating factor (CSF)-1-deficient osteopetrotic (Csf1 op /Csf1 op ) mice develop very little neointima, a finding attributed to impaired recipient macrophage function. We examined how CSF-1 affects neointima-derived vascular smooth muscle cells, tested the significance of CSF-1 expressed in donor tissue, and evaluated the contribution of secreted versus cell surface CSF-1 isoforms in transplant-associated arteriosclerosis. Methods and Results-CSF-1 activated specific signaling pathways to promote migration, survival, and proliferation of cultured vascular smooth muscle cells. Tumor necrosis factor-α addition increased CSF-1 and CSF-1 receptor expression, and tumor necrosis factor-α-driven proliferation was blocked by anti-CSF-1 antibody. In a mouse vascular allograft model, lack of recipient or donor CSF-1 impaired neointima formation; the latter suggests local CSF-1 function within the allograft. Moreover, reconstitution of donor or recipient cell surface CSF-1, without secreted CSF-1, restored neointimal formation. Conclusion-Vascular smooth muscle cells activation, including that mediated by tumor necrosis factor-α, can be driven in an autocrine/juxtacrine manner by CSF-1. These studies provide evidence for local function of CSF-1 in neointimal expansion, and identify CSF-1 signaling in vascular smooth muscle cells, particularly cell surface CSF-1 signaling, as a target for therapeutic strategies in transplant-associated arteriosclerosis. (Arterioscler Thromb Vasc Biol. 2013;33:87-95.)
T ransplant-associated arteriosclerosis (TA) is an accelerated form of vascular obstructive disease in graft arteries that limits long-term success of solid organ transplantation. 1 Advanced TA lesions contain a diffuse concentric neointima composed predominantly of vascular smooth muscle cells (VSMCs) and extracellular matrix proteins admixed with inflammatory cells. Compared with typical atherosclerosis, TA lesions contain less lipid, more infiltrating T cells and macrophages, and develop in months to years, rather than decades. Continuing neointimal expansion, restricted outward remodeling, and limited vasodilatory capacity impair arterial conduit function and lead ultimately to ischemia and graft failure. 2 Immunosuppressive regimens that successfully control acute rejection do not prevent TA. Whereas acute rejection is primarily destructive, TA is trophic-the result of progressive neointimal expansion. Early concepts of TA pathogenesis suggested that interferon (IFN)-γ-stimulated macrophages activated neointimal VSMCs by secreting cytokines, including tumor necrosis factor-α (TNF-α) and interleukin-1β, and growth factors such as platelet-derived growth factor (PDGF)-BB and basic fibroblast growth factor. There is considerable evidence that macrophages and VSMCs participate in an autonomous loop of mutual production and response to IFN-γ, even after initiating alloimmune responses have abated. 2, 3 Current models suggest 3 pathogenetically distinct stages in TA 2 : early nonspecific vascular injury, leading to inflammatory cell recruitment; subsequent alloimmune response, with T lymphocytes and macrophages augmenting endothelial and medial injury through cytokine production; and late phase neointimal expansion of VSMCs (or similar cells) in response to cytokines and chemokines.
Colony stimulating factor (CSF)-1 (also known as macrophage CSF, or M-CSF) is the primary regulator of survival, proliferation, and differentiation of macrophages. 4, 5 Osteopetrotic (op) mice possess an inactivating mutation in the Csf1 gene, and homozygous Csf1 op /Csf1 op mice are CSF-1-deficient and have profound defects in macrophage formation. 6 A macrophage role in TA pathogenesis was suggested by the finding that arterial allografts placed in Csf1 op /Csf1 op mice develop significantly less neointimal hyperplasia than those placed in wild-type (wt) mice. 7 It remains unclear, however, whether protection from TA in Csf1 op /Csf1 op mice stems from loss of local CSF-1 function and impaired activity of macrophages (or other host-derived cells) within the transplanted organ, or from systemic effects of CSF-1-deficiency that might impinge more generally on immune function.
CSF-1 is expressed by multiple cell types, including endothelial and VSMCs 6, 8 in 3 distinct isoforms: one membranespanning, cell surface isoform (csCSF-1), and 2 secreted isoforms (secCSF-1), proteoglycan and glycoprotein, found in the circulation. 4, 5 CSF-1 signals are mediated by the CSF-1 receptor tyrosine kinase (CSF-1R) encoded by the c-fms gene. 9 Among blood cells, the CSF-1R is expressed exclusively in cells of monocyte/macrophage lineage and their progenitors. 6 It is, however, also expressed in oocytes, trophoblastic cells, osteoclasts, and other cell types. 6 VSMCs in culture 10 and in neointima 11 can express CSF-1R and proliferate on stimulation by CSF-1, 11 but how CSF-1 affects other salient VSMC activities is unknown. Similarly, whereas signaling intermediates activated by CSF-1 in myeloid cells are known to include Src family kinases (SFKs), extracellular signal-regulated kinases (ERKs), and phosphoinositide kinase-3 (PI3K), 5,12 the signaling events downstream of the CSF-1R in VSMCs are unknown.
We recently developed and characterized several transgenic mouse lines useful for in vivo study of CSF-1 biology; these lines bear transgenes encoding selected isoforms of CSF-1 under control of the Csf-1 promoter and first intron. When this driver is coupled to a full length Csf-1 cDNA, the resultant transgene confers normal tissue-specific and developmental expression of CSF-1, including all 3 isoforms, and completely rescues the Csf1 op /Csf1 op phenotype. 13 Analogous transgenes expressing exclusively cs 14 or sec 15 CSF-1 provide only partial, nonredundant rescue. By using these mice as donors or recipients in vascular allograft experiments, we can examine contributions made by different CSF-1 isoforms in either donor-or recipient-derived cells. These strategies allow us to expand findings based in cell culture with in vivo studies addressing the following questions: (1) is CSF-1 expression in donor tissues important for TA, (2) do systemic (sec) and exclusively local (cs) CSF-1 contribute differentially to TA, and (3) do the different CSF-1 isoforms have similar or distinct roles in donor and recipient?
We now report that, in addition to proliferation, CSF-1 stimulates neointimal VSMC migration and survival, activities that may both contribute to neointimal accumulation. These findings are complemented by our in vivo results, which indicate that both donor and recipient-derived csCSF-1 drive neointimal formation in TA. Together, these studies describe CSF-1-mediated auto/juxtacrine enhancement of VSMC growth, migration, and survival within the vessel wall.
Methods

Mice
The CSF-1-deficient and 2 CSF-1 transgenic lines (Csf1 op /Csf1 op , TgN(FLCsf1)8Ers/+ (TgC/+), and TgN(CSCsf1)5Ers/+ (TgCS/+), respectively), were crossed onto or developed in the FVB genetic background for ≥7 generations, 13, 14 as were TgN(Csf1-Z)7Ers/+ (TgZ) mice, which express a LacZ reporter under control of Csf-1 regulatory elements. Transgene abbreviations are summarized in Table 1 .
Arterial Transplantation
Our mouse orthotopic carotid arterial transplantation model (CAT; see Figure IB in the online-only Data Supplement) has similarities to previously described aortic 16 and carotid arterial 17 transplant models. Transgenic donor-recipient combinations used are summarized in Table 2 , and relevant effects on csCSF-1, secCSF-1, and systemic macrophage levels are shown in Table 3 . Detailed descriptions of surgical methods, morphometry, cell culture, gene expression, and protein analyses can be found in the online-only Data Supplement.
Statistical Analysis
Quantitative results are expressed as mean±SEM. Experiments shown were performed in triplicate or quadruplicate, and are representative of at least 3 repeated experiments, using tissues/cells pooled from at least 3 mice per sample, except as noted in Figure legends . Potential differences among values from multiple samples were assessed by unpaired t test or factorial ANOVA followed by Bonferroni multiple comparison test when appropriate.
Results
CSF-1 Activates Multiple Signaling Pathways in Neointimal VSMCs
VSMCs derived from rat aortic media can proliferate in response to CSF-1. 11 In myeloid cells, kinases involved in CSF-1 signaling include SFKs, ERKs, and PI3Ks, 12 but pathways activated by CSF-1 in neointimal VSMCs have not been characterized. To permit such analyses, as well as additional studies using transgenic mice, we developed the CAT model. Orthotopic allografts showed prominent neointima formation containing admixed macrophages and proliferative VSMCs characteristic of TA ( Figure IA in the online-only Data Supplement). Of note, isograft CAT yielded negligible neointimal formation, indicating an essential role for histoincompatibility in this model. A full roster of donor-recipient combinations tested, designated groups I to VIII, is shown in Table 2 .
Allograft-derived primary VSMCs were prepared from CAT vessels ( Table 2 , group I) and used to evaluate activation-related phosphorylation of potential downstream targets 0 to 120 minutes after CSF-1 stimulation ( Figure  1A ). Phosphorylation of the PI3K target kinase Akt peaked at 5 minutes after stimulation and subsided thereafter to a level below baseline. Invariant phosphorylation of residue Tyr416 and dephosphorylation of Tyr527 suggested that Src kinase is constitutively active in these cells. On the other hand, we found substantial increases in phospho-ERK1/2 and phospho-p38 mitogen-activated protein kinase, both of which peaked 15 minutes after stimulation. Whereas ERK1/2 phosphorylation returned to near-baseline levels by 30 minutes, phospho-p38 remained elevated above basal activity levels through 120 minutes. Jun N-terminal kinase activity did not change after CSF-1 stimulation.
CSF-1 Mediates VSMC Growth, Migration, and Survival via Distinct Signaling Pathways
We then assessed how CSF-1 affected cellular activities critical to vascular remodeling, including growth, survival under oxidative stress, and migration, and examined the contribution of various signaling pathways. In bromodeoxyuridine (BrdU) incorporation assays of proliferation, we stimulated allograft-derived VSMCs with CSF-1 (50 ng/mL) in the presence of inhibitors of ERK (mitogen-activated protein kinase kinase [MEK] inhibitor PD98059), PI3K (wortmannin), p38 (SB203580), or SFKs (PP2). The ERK and SFK inhibitors suppressed CSF-1-induced BrdU incorporation to baseline levels, whereas the PI3K and p38 inhibitors had no effect ( Figure 1B CSF-1 has important pro-survival effects, mediated by PI3K and Akt, in myeloid cells, and tissue macrophages in vivo and primary macrophages in culture are largely dependent on CSF-1 for both survival and proliferation. 5 Whereas VSMC survival in routine culture is not CSF-1dependent, the CSF-1-mediated Akt phosphorylation we found ( Figure 1A ) suggested that CSF-1 might enhance VSMC survival in stressed conditions. VSMCs encounter oxidative stress in vivo via H 2 O 2 produced by macrophages, and H 2 O 2 is commonly used as a pro-apoptotic stimulus for cultured VSMCs. Exposure to 5 μmol/L H 2 O 2 caused readily detectable cell death in ≈20% of cells after 30 minutes ( Figure  1C ). CSF-1 treatment decreased this to ≈5%, indicating that CSF-1 has robust survival effects in allograft-derived VSMCs. Inhibition of PI3K totally reversed CSF-1-mediated survival, whereas inhibition of MEK, p38, and SFKs had little effect. Thus, CSF-1-mediated activation of PI3K promotes resistance of VSMCs to oxidative stress-induced cell death.
VSMC migration is also critical for neointimal formation. In Transwell assays, CSF-1 promoted VSMC chemotaxis; PDGF-BB, a very potent chemotactic stimulus, was tested for reference ( Figure 1D , left). Inhibitor studies showed that this effect of CSF-1 required MEK and p38 activities, and was independent of SFK and PI3K ( Figure 1D , right). Thus in these studies of allograft-derived VSMCs, CSF-1 stimulates multiple activities that contribute to VSMC accumulation in the arterial wall, and activates distinct combinations of signaling pathways to achieve each effect.
TNF-α Is a Major Inducer of Both CSF-1 and Its Receptor in Neointimal VSMCs
Medial and neointimal VSMCs harvested after vascular cannulation differ in their expression of CSF-1R. 18 To test whether neointimal VSMCs in allografted arteries differ from donor medial VSMCs in their ability to express CSF-1, we prepared untransplanted aortic (medial) VSMCs (FVB wt) and cells derived from day 42 allografts ( Table 2 , group I). By immunocytochemistry, both medial-and allograft-derived cells were largely positive for expression of the VSMC markers calponin, α-smooth muscle actin, and smooth muscle 22á, whereas macrophage markers CD68 and Mac3 were seen only rarely ( Figure III in the online-only Data Supplement and data not shown). Levels of Csf-1 and c-fms mRNA were measured by quantitative reverse transcription-polymerase chain reaction (Figure 2A ). Compared with medial cells, allograft-derived cells in 2% fetal bovine serum expressed higher levels of c-fms and similar levels of Csf-1 transcripts. Interestingly, these levels increased robustly in allograftderived cells stimulated with 20% fetal bovine serum. csCsf-1 mRNA levels were not serum-responsive in medial VSMCs, but more than doubled in allograft-derived VSMCs, whereas secCSF-1 transcripts increased more modestly. Similar patterns of overall expression and responsiveness were observed at the protein level ( Figure IV in the onlineonly Data Supplement). These results indicate that allograftderived, primarily neointimal VSMCs tend to express higher levels of both CSF-1R and csCSF-1 compared with medial VSMCs derived from normal arteries.
We then assessed how specific factors affected CSF-1 and CSF-1R expression in medial and allograft-derived cells. VSMCs from wt FVB mouse aortae and from group I grafts were stimulated with growth factors and cytokines previously reported to increase Csf-1 and c-fms transcript levels, 10 including PDGF-BB plus epidermal growth factor, TNF-α, and IFN-γ. Transcripts were measured by quantitative reverse transcription-polymerase chain reaction ( Figure 2B ). Of these factors, TNF-α and PDGF plus epidermal growth factor both induced Csf-1 and c-fms, with greater effects in neointimal than in medial VSMCs. Although the effect of IFN-γ effect was more modest, it showed selectivity for the csCsf-1 isoform, which is of particular interest given our in vivo findings (Figure 4 , below). Although neointimal VSMCs are generally known to be more proliferative and synthetic than their medial counterparts, 2 enhanced induction of both CSF-1 and its receptor in such cells has not been previously reported.
We also studied CSF-1 protein expression in allograftderived VSMCs stimulated with 2, 5, and 10 ng/mL of TNF-α for 48 hours, which allowed us to measure both secCSF-1 and csCSF-1 by ELISA ( Figure 2C ). Expression of both isoforms increased in a dose-dependent manner in response to TNF-α, consistent with the quantitative reverse transcription-polymerase chain reaction findings. These results point to TNFα as a potentially important stimulus for CSF-1 signaling in VSMCs. Indeed, TNF-α is known to contribute importantly to TA: TNF-α blockade inhibits neointimal formation in a rabbit TA model, 19 and interestingly, inactivation of TNF-α signaling specifically in donor tissue limits TA in allografted mouse hearts. 20 Such observations prompted us to explore a potential link between TNF-α and CSF-1 signaling. 
TNF-α Can Mediate VSMC Proliferation Via csCSF-1
In the studies described thus far, we used purified secCSF-1 to activate the CSF-1R. Recent studies of hematopoietic progenitor cells indicate that the cs isoform, csCSF-1, has more sustained growth stimulatory activity than sec isoforms. 21 Accordingly, we compared relative contributions of cs-and secCSF-1 in TNF-α-mediated stimulation of VSMCs. We first assessed whether csCSF-1 expressed on an allograft-derived, TNF-α-stimulated VSMC ( Table 2 , group I) feeder layer could stimulate proliferation in VSMC responders. These feeder layers were washed and then fixed with paraformaldehyde, leaving csCSF-1 as the only isoform present. 22 In overnight growth assays, nearly 40% of live VSMCs placed on fixed feeders from wt mice incorporated BrdU, compared with ≈20% in VSMCs placed on feeders derived from Csf1 op /Csf1 op mice ( Figure 3A ). Increased proliferation supported by wt versus CSF-1 deficient feeders is most likely attributable to expression of the csCSF-1 isoform by the former. By comparison, BrdU incorporation in VSMC responders separated from wt and CSF-1-deficient feeder cells by a porous membrane was lower, with no significant difference attributable to the presence or absence of CSF-1.
These findings point to a relatively strong proliferative stimulus mediated through direct contact involving the csCSF-1 isoform.
To test this mechanism in living cells, we isolated neointimal VSMCs that express only the csCSF-1 isoform by harvesting cells from TgCS carotid arteries subjected to the flow-cessation model of vascular injury. 23 These cells expressed the VSMC differentiation marker calponin and the CSF-1R, and increased csCSF-1 expression in response to TNF-α exposure ( Figure V in the online-only Data Supplement). We determined proliferation in BrdU incorporation assays after stimulation with TNF-α and exogenous CSF-1. To assess the role of CSF-1-mediated signaling, we added an anti-CSF-1 neutralizing antibody to some samples ( Figure 3B ). Exogenous CSF-1 increased proliferation ≈2-fold, an effect abolished by the antibody. TNF-α alone and TNF-α in combination with exogenous CSF-1 both increased proliferation; these effects were likewise reversed by the neutralizing antibody. CSF-1 acts exclusively through the CSF-1R, 9 so these findings indicate that the growth-promoting effects of both CSF-1 and TNF-α are mediated through the CSF-1R. Because these TgCS-derived VSMCs do not express secCSF-1, the CSF-1-mediated increase in proliferation after TNF-α stimulation indicates that VSMC proliferation can be regulated by csCSF-1 in a local, autocrine/juxtacrine fashion.
The csCSF-1 Isoform in Both Donor and Recipient Is Important in TA
We then evaluated the relative expression of relevant factors and CSF-1R and CSF-1 isoforms over an extended time course after transplantation. Transcripts encoding TNF-α, PDGF-BB, epidermal growth factor, and IFN-γ all peaked at Figure 4A ). CSF-1R (c-fms) transcripts were also elevated in allografted arteries, with highest levels also at day 29. Levels of sec and csCSF-1 transcripts showed some variation over time: secCSF-1 was relatively high at day 1, whereas both isoforms were increased at day 29. These data extend our findings in cultured VSMCs ( Figure 2B ) to the in vivo setting, showing expression of multiple factors in allografted arteries that may potentiate expression of CSF-1 and its receptor.
To identify the origin of cells in the grafted artery capable of expressing CSF-1, we used TgZ mice, in which the CSF-1 promoter/first intron drives expression of the LacZ gene in a pattern consistent with that of endogenous CSF-1. 13 We tested these mice as either donor or recipient and detected the LacZ gene product by 5-bromo-4-chloro-3-indolyl-â-D-galactopyranoside (X-gal) staining. Normal, untransplanted TgZ arteries showed no X-gal activity. With TgZ recipients at day 42, however, a significant fraction of neointimal cells was clearly X-gal-positive, whereas with TgZ donor tissue, X-gal-positive cells were found in the arterial media ( Figure VI in the onlineonly Data Supplement). Thus both donor and recipient cells contribute to total CSF-1 expression in the allograft. In addition, we assessed which cell types in the grafted artery could respond to CSF-1. Cultured neointimal cells stained positive for both VSMC markers and the CSF-1R ( Figures III and V in the online-only Data Supplement), whereas analyses of transplanted arterial sections showed CSF-1R immunostaining diffusely throughout the neointima ( Figure VII in the online-only Data Supplement). Taken together, these findings suggested the possibility of a local CSF-1 signaling network within the allografted artery, in which both donor and recipient cells express CSF-1, and VSMCs, as well as macrophages, express the CSF-1R and can respond to CSF-1.
To test this idea in vivo, we performed a series of vascular allografts using Csf1 op /Csf1 op mice, reconstituted by transgenesis with specific CSF-1 isoforms, as recipients or donors in CAT. Representative immunohistochemical sections from wt allografts placed in wt transgenic mice are shown in Figure  4B (group I). Neointimal formation in wt grafts placed in mice lacking all CSF-1 (Csf1 op /Csf1 op ; group II) was markedly attenuated, consistent with a previous study. 7 Such a reduction was not seen in transgenic recipients expressing both sec and csCSF-1 (group III) or those expressing csCSF-1 only (group IV). This series of transplants shows that whereas recipient CSF-1 is essential for neointimal formation, the cs isoform alone is sufficient to drive neointimal formation, and the sec isoform is not required in the recipient.
We also tested the importance of CSF-1 in donor tissues by transplanting arteries from mice with varied expression of CSF-1 into wt recipients. As shown in Figure 4C , arteries from mice lacking CSF-1 (group VI) developed significantly smaller neointimas than those from wt controls with physiological CSF-1 expression (group V). Donor arteries from mice with essentially normal levels of circulating CSF-1 and substantially reduced csCSF-1 13 also showed impaired neointimal formation (group VII). On the other hand, transplanted arteries originating from mice with negligible circulating CSF-1 and near wt levels of csCSF-1 13 showed complete restoration of neointimal formation (group VIII, Figure 4C ). These findings show that local (donor) expression of the csCSF-1 isoform is necessary and sufficient for neointimal formation. Taken together with the recipient studies shown in Figure 4B , these results define an important role in TA for csCSF-1 produced by both donor and recipient tissues.
Selective csCSF-1 Activity in the Recipient Uncouples Neointimal Formation and Inflammation
Although grafts placed in recipients expressing only csCSF-1 showed full restoration of neointimal formation, these arteries appeared to have fewer inflammatory cells Figure 4 . The cell surface colony stimulating factor (csCSF)-1 isoform drives neointimal formation in allografted carotid arteries. A, Quantitative reverse transcription-polymerase chain reaction analysis of cytokine, growth factor, c-fms, and Csf1 isoform expression, in group I allografts at postoperative days 0, 1, 6, 29, and 42, with correction relative to rpl13a levels. Allografts were pooled (n=3 per time point) for RNA processing and evaluation. B, C, Representative hematoxylin-eosin stained allograft cross-sections 42 days after transplantation. Groups I to VIII are described in Table 2 . Arrowheads indicate the internal elastic lamina. Scale bars, 200 μm. B, Manipulation of CSF-1 expression in donor tissue. Left, wt donor arteries placed in recipients expressing indicated CSF-1 isoforms. Right, quantitative evaluation: *P<0.05; **P<0.01. C, Manipulation of CSF-1 expression in the recipient. Left, Donor arteries from FVB mice expressing indicated CSF-1 isoforms, placed in wt Balb/C recipients. Right, Quantitative evaluation, *P<0.05. IFN indicates interferon; TNF, tumor necrosis factor; PDGF, platelet-derived growth factor; EGF, epidermal growth factor; wt, wild type; sec, secreted. than seen in other combinations with robust neointimal formation ( Figure 4B , compare group IV versus groups I, III). Quantitation of the fraction of neointimal area occupied by nuclei in hematoxylin-eosin stained sections supported this observation ( Figure 5A ). To evaluate inflammatory activity, we performed immunohistochemical staining for the macrophage activation marker Mac3 ( Figure 5B ) and quantitated the fraction of cells positive for this marker ( Figure  5C ). In this analysis, groups II, III, and IV all scored lower than group I, indicating lower inflammation with any reduction in total Csf-1 expression in the recipient. Not surprisingly, the small neointimas from group II (in which recipients lack any Csf-1 and have globally reduced macrophage numbers) showed the lowest Mac3 activity; on other hand, group IV arteries showed a similar decrease in Mac3, despite their robust neointimas. Analysis of grafts with differing CSF-1 isoform expression placed in wt Balb/C recipients showed that neointimas from all groups stained diffusely for Mac3, regardless of differences in donor CSF-1 (groups V-VIII, not shown). These results indicate that neointimal formation does not necessarily correlate with infiltration of the graft by inflammatory cells, consistent with findings we 24 and others 25 have reported previously. Based on this analysis of day 42 grafts, we cannot exclude the possibility that the different CSF-1 isoforms affect pathogenetically significant inflammatory states at earlier time points. In the context of the present work, however, these observations suggest that factors driving VSMC accumulation in the neointima are still active when the recipient mouse lacks secCSF-1 and its associated inflammatory infiltrate.
Discussion
Our findings demonstrate that expression of the cs isoform of CSF-1 by both donor and recipient-derived cells is important for neointimal formation in a mouse model of TA. Although CSF-1 is best characterized as the primary factor promoting growth, survival, and differentiation of the monocyte/macrophage lineage, 12 we find that CSF-1 can directly stimulate growth, migration, and survival of VSMCs, key activities that promote TA. Moreover, our results suggest an autocrine/juxtacrine regulatory mechanism in which VSMC accumulation is promoted by locally expressed csCSF-1 acting via the CSF-1R. These studies do not test the significance of CSF-1 isoforms in early inflammatory events that may contribute to eventual neointimal formation, though our cell culture and in vivo findings suggest the formation of a growth-and survival-promoting loop that does not depend on continued presence of inflammatory cells (ie, those recruited by secCSF-1, and lacking in csCSF-1-only recipients) at later time points within the established neointima.
Multiple studies point to an important role for CSF-1 in vascular pathology, but the precise nature of this contribution is unclear, and the possibility that sec and csCSF-1 isoforms contribute differentially to vascular disease has not been assessed previously. Decreased TA in Csf-1 op /Csf-1 op transplant recipient mice, which lack all CSF-1, was attributed to systemic monocyte/macrophage depletion. 7 Similarly, decreased lipiddriven (native vessel) atherosclerosis in LDLR −/− ; Csf-1 op/+ mice was attributed to local CSF-1 acting to recruit and activate macrophages in the vessel wall. 26 Nevertheless, the CSF-1R is expressed by cells other than monocyte/macrophages, including cultured VSMCs. 11 Our findings both in vivo and in vitro provide evidence that CSF-1 acting locally in the vessel wall directly supports VSMC accumulation, as well as activating monocyte/macrophages, and suggest that this signaling axis is an important part of the contribution of CSF-1 to vascular pathogenesis.
Our results focus attention on the csCSF-1 isoform. Both sec and csCSF-1 isoforms were expressed in transplanted arteries (Figure 4 ), but restoration of neointimal formation in donor arteries otherwise lacking CSF-1 was only achieved with wt levels of the csCSF-1 isoform-the sec isoform was not sufficient. Neointimal VSMCs derived from day 42 allografts expressed more CSF-1 than normal aortic medial VSMCs, and csCSF-1 appeared more responsive to stimuli than secCSF-1, as seen in other cell types. 27 Interestingly, the csCSF-1 isoform mediates comparatively more sustained proliferative effect on hematopoietic progenitors. 21 Neointimal VSMCs also expressed more CSF-1R. Thus both ligand and receptor components of the CSF-1 regulatory loop are preferentially increased in neointimal VSMCs, and are notably responsive to the inflammatory mediator TNFα. Although monocyte/macrophages are the major source of systemic TNF-α, VSMCs can also produce this cytokine 28thus CSF-1-mediated VSMC effects may be augmented by TNF-α derived from infiltrating inflammatory cells or from neointimal VSMCs. Interestingly, whereas IFN-γ yielded significantly lower Csf-1 mRNA induction than TNF-α, its effect was selective for csCSF-1.
In the clinical setting, TA has proven largely refractory to immunosuppressive therapies that prevent acute rejection. Clinical studies using agents such as sirolimus, which has both immunosuppressive and anti-proliferative activity, showed promising results 1 year after heart transplantation 29 and in recent nonrandomized but longer term protocols, 30 consistent with the idea that control of immune cell proliferation may be key to prevention of neointimal formation and vascular obstruction. Our findings support this approach, while also pointing to control of VSMC proliferation as a desirable therapeutic goal in TA.
Understanding the role of CSF-1/CSF-1R signaling in neointimal formation has additional implications for the development of therapies to prevent TA. For one, suppression of immune cell function, whether directed at acquired lymphocytedirected or innate macrophage-dependent immune responses, may do little to slow neointimal VSMC proliferation once the autocrine/juxtacrine CSF-1/CSF-1R loop is established. Factors that support this loop may prove to be better targets for intervention. In the mechanism we have outlined, these targets include TNF-α, as an important inducer of CSF-1 signaling in neointimal VSMCs, CSF-1 itself, and CSF-1R and its downstream mediators. Indeed, local TNF-α expression increases in neointimal VSMCs responding to mechanical arterial injury, 28 and previous studies have shown that inhibition of TNF-α activity can limit neointimal formation. 19, 20 Like TNF-α, CSF-1 and CSF-1R targets are amenable to blockade by antibodies 31, 32 or with pharmacological inhibitors. 33, 34 Our findings suggest utility of even more selective therapies, perhaps via RNA interference or other approaches, which might be developed to specifically target csCSF-1.
Signaling pathways downstream of the CSF-1R in VSMCs may also provide targets for intervention. Structure-function analyses indicate that the outcome of CSF-1R activation can vary with cell type 5 -thus signaling mechanisms defined in macrophages are not necessarily active in VSMCs. Consistent with studies in macrophages, 5 we found that SFK and MEK/ ERK pathways are necessary for CSF-1-stimulated VSMC proliferation, but not survival in the setting of oxidative stress, whereas the PI3K/Akt pathway is not essential for proliferative effects, but is required for survival. Conversely, we did not see a decrease in VSMC proliferation with PI3K inhibition, in distinction to a report that both PI3K/Akt and ERK signaling are required for optimal CSF-1-mediated mitogenesis in macrophages. 35 To our knowledge, CSF-1-mediated chemotaxis of VSMCs has not been described previously; we find that it depends on the activities of both MEK and p38 mitogenactivated protein kinase, but not PI3K-unlike CSF-1-mediated migration in macrophages, which is PI3K-dependent. 36 Additional studies of VSMC-specific aspects of CSF-1-stimulated signaling may lead to identification of new targets more selective for this cell type, and in turn, to therapies that spare macrophage function and avoid further compromise of transplant recipient immunity.
